ArticleRespiratory medicine2021
Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study.
Article in Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prevalence of Gastroesophageal reflux disease in patients with Idiopathic pulmonary fibrosis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Examining Cough's Role and Relief Strategies in Interstitial Lung Disease.Journal of clinical medicine · 2025Review
- Article
- A multi-level investigation of the genetic relationship between gastroesophageal reflux disease and lung cancer.Translational lung cancer research · 2024Article
- Determinants of cough-related quality of life in interstitial lung diseases.BMC pulmonary medicine · 2024Article
- Review
- Article
- Chinese expert consensus on diagnosis and management of gastroesophageal reflux disease in the elderly (2023).Aging medicine (Milton (N.S.W)) · 2024Article
- Association between Antacid Exposure and Risk of Interstitial Lung Diseases.Tuberculosis and respiratory diseases · 2024Article
- Nationwide Study of the Epidemiology, Diagnosis, and Treatment of Hypersensitivity Pneumonitis in Korea.Journal of Korean medical science · 2024Article
- Linking the impact of aspiration to host variables using the BOLUS framework: support from a rapid review.Frontiers in rehabilitation sciences · 2024Review
- Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix.Frontiers in pharmacology · 2024Article
- Selective dysfunction of the crural diaphragm in patients with chronic restrictive and obstructive lung disease.Neurogastroenterology and motility · 2024Article
- Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: a mendelian randomization study.BMC pulmonary medicine · 2023Article
- Relationship Between Esophageal Disease and Pulmonary Fibrosis.Digestive diseases and sciences · 2023Review
- Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know.Current rheumatology reports · 2022Review
- Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIt is unknown whether gastroesophageal reflux disease (GERD) is a risk factor or consequence of idiopathic pulmonary fibrosis (IPF). This study aimed to determine whether patients with IPF were more likely to have GERD compared with age- and sex-matched controls who either had 1) interstitial lung disease (ILD) other than IPF or 2) no diagnosed lung disease (population control).
methodsWe used the medical records-linkage system of the Rochester Epidemiology Project (REP) to identify patients with IPF who resided in Olmsted County, Minnesota, from January 1, 1997, through June 30, 2017. IPF cases were each matched with patients from 2 control groups (non-IPF ILD controls and population controls). We used conditional logistic regression to model associations between GERD diagnosis and IPF case status. P values were adjusted for multiple comparisons by using the Bonferroni adjustment (P values < .025 were considered statistically significant).
resultsOne hundred thirteen IPF cases were identified and matched to 226 population controls and 226 controls with non-IPF ILD. After multivariable adjustment, the odds of having GERD were 1.78 times higher (95% CI, 1.09-2.91; P = .02) in IPF cases compared with population controls. After multivariable adjustment, the odds of having GERD were 0.46 times lower (95% CI, 0.23-0.94; P = .03) in IPF cases compared with non-IPF ILD controls.
conclusionGERD may be an important contributor to the development of lung fibrosis. Thus, it should be investigated and addressed adequately when detected in patients with IPF and patients with non-IPF ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.